Adverse reactions to first-time antituberculosis drugs

Expert Opinion on Drug Safety

Volumn 5, Issue 2, 2006, Pages 231-249

  Forget, Eric J ^a   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Drug induced hepatitis; Ethambutol; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis (TB)

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; BICARBONATE; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; DIAZEPAM; DISULFIRAM; DOPAMINE; ETHAMBUTOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PARACETAMOL; PLACEBO; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; SEROTONIN; STREPTOMYCIN; THEOPHYLLINE; TRIAZOLAM; TRYPTAMINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; WARFARIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACNE; ACUTE INTERMITTENT PORPHYRIA; ACUTE KIDNEY TUBULE NECROSIS; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; AGRANULOCYTOSIS; ALOPECIA; ALOPECIA AREATA; AMENORRHEA; AMNESIA; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANURIA; APLASTIC ANEMIA; AREFLEXIA; ARTHRALGIA; ASEPTIC MENINGITIS; ATROPHY; BLINDNESS; BONE PAIN; BRAIN EDEMA; BRAIN HEMORRHAGE; BREAST FEEDING; BULLOUS SKIN DISEASE; BURNING SENSATION; CEREBELLAR ATAXIA; CHILD; CHILL; CHOLESTASIS; CLINICAL TRIAL; COLITIS; COMA; CONCENTRATION LOSS; CONFUSION; CONJUNCTIVITIS; CONVULSION; COOMBS POSITIVE HEMOLYTIC ANEMIA; CRANIAL NEUROPATHY; DEMYELINATION; DIARRHEA; DISEASE EXACERBATION; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INTOXICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHORIA; DYSPNEA; EOSINOPHILIA; ERYTHEMA; ERYTHEMA MULTIFORME; ESOPHAGITIS; EXFOLIATIVE DERMATITIS; EYE TOXICITY; FEVER; FLU LIKE SYNDROME; FLUID THERAPY; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GOUT; GRANULOCYTOPENIA; GRANULOMATOUS HEPATITIS; GRAY MATTER; HAIR LOSS; HALLUCINOSIS; HEADACHE; HEARING LOSS; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEMOPHAGOCYTIC SYNDROME; HEPATITIS; HEPATOSPLENOMEGALY; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERURICEMIA; HYPOGLYCEMIA; HYPOPROTHROMBINEMIA; HYPOTENSION; HYPOTHYROIDISM; INCIDENCE; INFANT; INTERSTITIAL NEPHRITIS; INTERSTITIAL PNEUMONIA; IRRITABILITY; JAUNDICE; KIDNEY DISEASE; KIDNEY FAILURE; LENS LUXATION; LEUKOPENIA; LICHENOID ERUPTION; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LUNG INFILTRATE; LUPUS ERYTHEMATOSUS; LYMPHADENOPATHY; MACULOPAPULAR RASH; MENTAL DISEASE; METABOLIC ACIDOSIS; MORBIDITY; MORTALITY; MOUTH ULCER; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; MYOPATHY; NAUSEA; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; NONTHROMBOCYTOPENIC PURPURA; OCCUPATIONAL ASTHMA; OLIGOMENORRHEA; OLIGURIA; OPTIC NERVE DISEASE; OPTIC TRACT; ORGANIC BRAIN SYNDROME; OTOTOXICITY; PAIN; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PATIENT COMPLIANCE; PELLAGRA; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PERIPHERAL NEUROPATHY; PHOTOALLERGY; PHOTODERMATOSIS; PORPHYRIA CUTANEA TARDA; PREGNANCY; PROTEINURIA; PRURITUS; PSYCHOSIS; PURE RED CELL ANEMIA; PURPURA; PUSTULE; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; SEIZURE; SHOCK; SIDE EFFECT; SIDEROBLASTIC ANEMIA; SKIN DISCOLORATION; SKIN DISEASE; SKIN MANIFESTATION; SKIN TINGLING; SLURRED SPEECH; STEVENS JOHNSON SYNDROME; STREPTOMYCES GRISEUS; STRIA; STUPOR; TACHYCARDIA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS; URTICARIA; VERTIGO; VESICULAR RASH; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; LUNG TUBERCULOSIS; PATHOPHYSIOLOGY; RISK FACTOR; TOXIC HEPATITIS;

AGE FACTORS; ANTITUBERCULAR AGENTS; DRUG HYPERSENSITIVITY; GASTROINTESTINAL DISEASES; HEPATITIS, TOXIC; HUMANS; INCIDENCE; KIDNEY FAILURE; MORBIDITY; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 33644902345     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.2.231     Document Type: Review

References (252)

1. CORBETT EL, WATT CJ, WALKER N et al.: The growing burden of tuberculosis - global trends and interactions with the HIV epidemic. Arch. Int. Med. (2003) 163:1009-1021.
2. AMERICAN THORACIC SOCIETY/CENTERS FOR DISEASE CONTROL AND PREVENTION/INFECTIOUS DISEASE SOCIETY OF AMERICA: Treatment of tuberculosis. Am. J. Respir. Crit. Care Med (2003) 167:603-622.
3. AMERICAN THORACIC SOCIETY: Targeted tuberculin skin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. (2000) 161:S221-S247.
4. SARMA GR, IMMANUEL C, KAILASAM S, NARAYANA ASL, VENKATESAN P: Rifampin-induced release of hydrazine from isoniazid - a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am. Rev. Respir. Dis. (1986) 133:1072-1075.
5. ELLARD GA: The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle (1984) 65:211-227.
6. ELLARD GA, MITCHISON DA, GIRLING DJ, NUNN AJ, FOX W: The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug. Am. Rev. Respir. Dis. (1978) 118:628-629.
7. MITCHELL JR, THORGEIRSSON UP, BLACK M et al.: Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin. Pharmacol. Ther. (1975) 18:70-79.
8. MITCHELL JR, ZIMMERMAN HJ, ISHAK KG et al.: Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann. Int. Med (1976) 84:181-192.
9. SCHARER L, SMITH JP: Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann. Int. Med. (1969) 71:1113-1120.
10. BLACK M, MITCHELL JR, ZIMMERMAN HJ, ISHAK KG, EPLER GR: Isoniazid-associated hepatitis in 114 patients. Gastroenterology (1975) 69:289-302.
11. MADDREY WC, BOITNOTT JK: Isoniazid hepatitis. Ann. Int. Med. (1973) 79:1-12.
12. VEENING GJJ: Long term isoniazid prophylaxis - controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull. Int. Union Tuberc. Lung Dis. (1968) 41:169-171.
13. MOUNT FW, FEREBEE SH: Preventive effects of isoniazid in the treatment of primary tuberculosis in children. N. Engl. J. Med. (1961) 265:713-721.
14. FEREBEE SH, MOUNT FW, ANASTASIADES AA: Prophylactic effects of isoniazid on primary tuberculosis in children - a preliminary report. Am. Rev. Tuberc. (1957) 76:942-963.
15. FEREBEE SH, MOUNT FW: Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am. Rev. Respir. Dis. (1962) 85:490-510.
16. MOUNT FW, FEREBEE SH: The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am. Rev. Respir. Dis. (1962) 85:821-827.
17. FEREBEE SH, MOUNT FW, MURRAY FJ, LIVESAY VT: A controlled trial of isoniazid prophylaxis in mental institutions. Am. Rev. Respir. Dis. (1963) 88:161-175.
18. COMSTOCK GW, FEREBEE SH, HAMMES LM: A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am. Rev. Respir. Dis. (1967) 95:935-943.
19. EGSMOSE T, ANG'AWA JOW, POTI SJ: The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull. Wld. Hlth. Org. (1965) 33:419-433.
20. HORWITZ O, PAYNE PC, WILBEK E: Epidemiological basis of tuberculosis eradication - the isoniazid trial in greenland. Bull. Wld. Hlth. Org. (1966) 35:509-526.
21. KATZ J, KUNOFSKY S, DAMIJONAITIS V, LAFLEUR A, CARON T: Effect of isoniazid upon the reactivation of inactive tuberculosis - a final report. Am. Rev. Respir. Dis. (1965) 91:345-350.
22. BUSH OB, SUGIMOTO M, FUJII Y, BROWN FA JR: Isoniazid prophylaxis in contacts of persons with known tuberculosis - second report. Am. Rev. Respir. Dis. (1965) 92:732-740.
23. COMSTOCK GW, HAMMES LM, PIO A: Isoniazid prophylaxis in Alaskan boarding schools - a comparison of two doses. Am. Rev. Respir. Dis. (1969) 100:773-779.
24. GRZYBOWSKI S, ASHLEY MJ, MCKINNON NE, PINKUS C, PHILLIPS R, BROVN A: In Canada: a trial of chemoprophylaxis in inactive tuberculosis. Canad. Med. Ass. J. (1969) 101:81-86.
25. FEREBEE SH: Controlled chemoprophylaxis trials in tuberculosis - a general review. Adv. Tuberc. Res. (1970) 17:28-106.
26. GARIBALDI RA, DRUSIN RE, FEREBEE SH, GREGG MB: Isoniazid-associated hepatitis - report of an outbreak. Am. Rev. Respir. Dis. (1972) 106:357-365.
27. AMERICAN THORACIC SOCIETY MEDICAL SECTION OF THE NATIONAL TUBERCULOSIS ASSOCIATION: Chemoprophylaxis for the prevention of tuberculosis - a statement by an Ad hoc committee. Am. Rev. Respir. Dis. (1967) 96:558-560.
28. KOPANOFF DE, SNIDER DE JR, CARAS GJ: Isoniazid-related hepatitis. Am. Rev. Resp. Dis. (1978) 117:991-1001.
29. THOMPSON NJ: Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull. Wld. Hlth. Org. (1982) 60:555-564.
30. NOLAN CM, GOLDBERG SG, BUSKIN SE: Hepatotoxicity associated with isoniazid preventive therapy - a 7-year survey from a public health tuberculosis clinic. JAMA (1999) 281:1014-1018.
31. BEAUDRY PH, BRICKMAN HF, WISE MB, MACDOUGALL D: Liver enzyme disturbances during isoniazid chemoprophylaxis in children. Am. Rev. Respir. Dis. (1974) 110:581-584.
32. BYRD RB, HORN BR, SOLOMON DA, GRIGGS GA: Toxic effects of isoniazid in tuberculosis chemoprophylaxis - role of biochemical monitoring in 1,000 patients. JAMA (1979) 241:1239-1124.
33. DASH LA, COMSTOCK GW, FLYNN JPG: Isoniazid preventive therapy - retrospect and prospect. Am. Rev. Respir. Dis. (1980) 121:1039-1044.
34. STEAD WM, TO T, HARRISON RW, ABRAHAM JH: Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann. Int. Med. (1987) 107:843-845.
35. FRANKS AL, BINKIN NJ, SNIDER DE Jr, ROKAW WM, BECKER S: Isoniazid hepatitis among pregnant and postpartum hispanic patients. Public Health Rep. (1989) 104:151-155.
36. LOBUE PA, MOSER KS: Use of isoniazid for latent tuberculosis infection in a public health clinic. Am. J. Respir. Crit. Care Med. (2003) 168:443-447.
37. MOULDING TS, REDEKER AG, KANEL GC: Twenty isoniazid-associated deaths in one state. Am. Rev. Respir. Dis. (1989) 140:700-705.
38. HALPERN M, MEYERS B, MILLER C et al.: Severe isoniazid-associated hepatitis - New York, 1991-1993. JAMA (1993) 270:809.
39. SNIDER DE, CARAS GJ: Isoniazid-associated hepatitis deaths: a review of available information. Am. Rev. Respir. Dis. (1992) 145:494-497.
40. AMERICAN THORACIC SOCIETY: Preventive treatment of tuberculosis. Am. Rev. Respir. Dis. (1971) 104:460-465.
41. AMERICAN THORACIC SOCIETY: Preventive therapy of tuberculosis infection. Am. Rev. Respir. Dis. (1974) 110:371-374.
42. MEHTA JB, DUTT AK, HARVILL L, HENRY W: Isoniazid preventive therapy for tuberculosis - are we losing our enthusiasm? Chest (1988) 94:138-141.
43. SALPETER SR: Fatal isoniazid-induced hepatitis - its risk during chemoprophylaxis. West. J. Med. (1993) 159:560-564.
44. MILLARD PS, WILCOSKY TC, READE-CHRISTOPHER SJ, WEBER DJ: Isoniazid-related fatal hepatitis. West. J. Med. (1996) 164:486-491.
45. COMSTOCK GW, EDWARDS pQ: The competing risk of tuberculosis and hepatitis for adult tuberculin reactors. Am. Rev. Resp. Dis. (1975) 111:573-577.
46. ROSE DN, SCHECHTER CB, SILVER AL: The age threshold for isoniazid chemoprophylaxis - a decision analysis for low-risk tuberculin reactors. JAMA (1986) 256:2709-2713.
47. JORDAN TJ, LEWIT EM, REICHMAN LB: Isoniazid preventive therapy for tuberculosis - decision analysis considering ethnicity and gender. Am. Rev. Respir. Dis. (1991) 144:1357-1360.
48. SALPETER SR, SANDERS GD, SALPETER EE, OWENS DK: Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age - a risk-benefit and cost-effectiveness analysis. Ann. Int. Med. (1997) 127:1051-1061.
49. TAYLOR WC, ARONSON MD, DELBANCO TL: Should young adults with a positive tuberculin test take isoniazid? Ann. Int. Med. (1981) 94:808-813.
50. TSEVAT J, TAYLOR WC, WONG JB, PAUKER SG: Isoniazid for the tuberculin reactor: take it or leave it. Am. Rev. Respir. Dis. (1988) 137:215-220.
51. FERNANDEZ-VILLAR A, SOPENA B, VASQUEZ R et al.: Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin. Infect. Dis. (2003) 36:293-298.
52. BENITO N, SUED O, MORENO A et al.: Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation (2002) 74:1381-1386.
53. RISKA N: Hepatitis cases in isoniazid treated groups and in a control group. Bull. Int. Union Tuberc. (1976) 51:203-208.
54. SADAPHAL P, ASTEMBORSKI J, GRAHAM NMH et al.: Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin. Infect. Dis. (2001) 33:1687-1691.
55. MCGLYNN CA, LUSTBADER ED, SHARRAR RC, MURPHY EC, LONDON WT: Isoniazid prophylaxis in hepatitis B carriers. Am. Rev. Resp. Dis. (1986) 134:666-668.
56. HAWKEN MP, MEME HK, ELLIOTT LC et al.: Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS (1997) 11:875-882.
57. GORDIN FM, MATTS JP, MILLER C et al.: A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N. Engl. J. Med. (1997) 337:315-320.
58. ORMEROD LP, HORSFIELD N: Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tubercle Lung. Dis. (1996) 77:37-42.
59. GRONHAGEN-RISKA C, HELLSTROM PE, FROSETH B: Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am. Rev. Respir. Dis. (1978) 118:461-466.
60. YEW WW: Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations. Int. J. Tuberc. Lung Dis. (2001) 5:99-101.
61. GURUMURTHY P, KRISHNAMURTHY MS, NAZARETH O et al.: Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis. Am. Rev. Respir. Dis. (1984) 129:58-61.
62. MITCHELL JR, LONG MW, THORGEIRSSON UP, JOLLOW DJ: Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest (1975) 68:181-190.
63. BERNSTEIN RE: Isoniazid hepatotoxicity and acetylation during tuberculosis chemoprophylaxis. Am. Rev. Respir. Dis. (1980) 121:429-430.
64. OHNO M, YAMAGUCHI I, YAMAMOTO I et al.: Slow n-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung. Dis. (2000) 4:256-261.
65. BYRD RB, HORN BR, GRIGGS GA, SOLOMON DA: Isoniazid chemoprophylaxis - association with detection and incidence of liver toxicity. Arch. Int. Med. (1977) 137:1130-1133.
66. BAILEY WC, TAYLOR SL, DASCOMB HE, GREENBERG HB, ZISKIND MM: Disturbed hepatic function during isoniazid chemoprophylaxis. Am. Rev. Respir. Dis. (1973) 107:523-529.
67. BAILEY WC, WEILL H, DEROUEN TA, ZISKIND MM, JACKSON HA, GREENBERG HB: The effect of isoniazid on transaminase levels. Ann. Int. Med. (1974) 81:200-202.
68. BYRD RB, NELSON R, ELLIOTT RC: Isoniazid toxicity - a prospective study in secondary chemoprophylaxis. JAMA (1972) 220:1471-1473.
69. SPYRIDIS P, SINANIOTIS C, PAPADEA I, OREOPOULOS L, HADJIYIANNIS S, PAPADATOS C: Isoniazid liver injury during chemoprophylaxis in children. Arch. Dis. Child (1979) 54:65-67.
70. HOLDINESS MR: Adverse cutaneous reactions to antituberculous drugs. Int. J. Dermatol. (1985) 24:280-285.
71. SCHABERG T, REBHAN K, LODE H: Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J. (1996) 9:2026-2030.
72. SCHEID P, KANNY G, TRECHOT P et al.: Isoniazid-induced bullous skin reaction. Allergy (1999) 54:294-296.
73. YAMASAKI R, YAMASAKI M, KAWASAKI Y, NAGASAKO R: Generalized pustular dermatosis caused by isoniazid. Br. J. Dermatol. (1985) 112:504-506.
74. MURATAKE T, WATANABE H, HAYASHI S: Isoniazid-induced pellagra and the n-acetyltransferase gene genotype. Am. J. Psychiatry (1999) 156:660.
75. DARVAY A, BASARAB T, MCGREGOR JM RUSSELL-JONES R: Isoniazid induced pellagra despite pyridoxine supplementation. Clin. Exp. Dermatol. (1999) 24:167-170.
76. SHARMA PK, GAUTAM RK, BHARDWAJ M, KAR HK: Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption. J. Dermatol. (2001) 28:737-741.
77. DASTA JF, PRIOR JA, KURZROK S: Isoniazid-induced fever. Chest (1979) 75:196-197.
78. JACOBS NF, THOMPSON III SE: Spiking fever from isoniazid simulating a septic process. JAMA (1977) 238:1759-1760.
79. GABRAIL NY: Severe febrile reaction to isoniazid. Chest (1987) 91:620-621.
80. CROOK MJ: Isoniazid-induced anaphylaxis. J. Clin. Pharmacol. (2003) 43:545-546.
81. KIM JH, KIM HB, KIM BS, HONG SJ: Rapid oral desensitization to isoniazid, rifampin, and ethambutol. Allergy (2003) 58:540-541.
82. MCCURDY PR, DONOHOE RF: Pyridoxine-responsive anemia conditioned by isonicotinic acid hydrazide. Blood (1966) 27:352-362.
83. FERSUSON A: Agranulocytosis during isoniazid therapy. Lancet (1952) 260:1179.
84. CORMICAN LJ, SCHEY S, MILBURN HJ: G-CSF Enables completion of tuberculosis therapy associated with iatrogenic neutropenia. Eur. Respir. J. (2004) 23:649-650.
85. HOLDINESS MR: A review of blood dyscrasias induced by the antituberculosis drugs. Tubercle (1987) 68:301-309.
86. CLAIBORNE RA, DUTT AK: Isoniazid-induced pure red cell aplasia. Am. Rev. Respir. Dis. (1985) 131:947-949.
87. MARSEGLIA GL, LOCATELLI F: Isoniazid-induced pure red cell aplasia in two siblings. J Pediatr. (1998) 132:898-900.
88. JAIN D, DASH S: Pancytopenia due to extensive hemophagocytosis following antitubercular treatment. Am. J. Hematol. (2004) 75:115-120.
89. WOOD JD, PEEKSER sJ: A correlation between changes in gABA Metabolism and isonicotinic acid hydrazide-induced seizures. Brain Res. (1972) 45:489-498.
90. REEVES RR, LIBERTO V: Confusion associated with isoniazid-induced pyridoxine deficiency. Psychosomatics (2004) 45:537-538.
91. LEWIN PK, MCGREAL d: Isoniazid toxicity with cerebellar ataxia in a child. Can. Med. Assoc. J. (1993) 148:49-50.
92. GOLDMAN AL, BRAMAN SS: Isoniazid: a review with emphasis on adverse effects. Chest (1972) 62:71-77.
93. DEVADATTA S, GANGADHARAM PRJ, ANDREWS RH et al.: Peripheral neuritis due to isoniazid. Bull. Wld. Hlth. Org. (1960) 23:587-598.
94. REILLY RH, KILLAM KF, JENNEY EH et al.: Convulsant effects of isoniazid. JAMA (1953) 152:1317-1321.
95. REIDER HL: Interventions for tuberculosis control and elimination. International union against tuberculosis and lung disease, Paris, France (2002):1-251.
96. ALAO AO, YOLLES JC: Isoniazid-induced psychosis. Ann. Pharmacother. (1998) 32:889-891.
97. OLSEN PZ, TORNING K: Isoniazid and loss of memory. Scand. J. Resp. Dis. (1968) 49:1-8.
98. ALTIPARMAK MR, PAMUK ON, PAMUK, GE, ATAMAN R, SERDENGECTL K: Is isoniazid ototoxic in patients undergoing hemodialysis? Nephron (2002) 92:478-480.
99. KASS I, MANDEL W, COHEN H, DRESSLER SH: Isoniazid as a cause of optic neuritis and atrophy. JAMA (1957) 164:1740-1743.
100. JIMENEZ-LUCHO VE, DEL BUSTO R, ODEL J: Isoniazid and ethambutol as a cause of optic neuropathy. Eur. J. Respir. Dis. (1987) 71:42-45.
101. DOMPELING E, SCHUT E, VLES H, KOOYMAN M, JOBSIS Q, HENDRIKS H: Diplopia and strabismus convergens mimicking symptoms of tuberculous meningitis as side-effects of isoniazid. Eur. J. Pediatr. (2004) 163:503-504.
102. WHITEFIELD CL, KLEIN RG: Isoniazid overdose: report of 40 patients, with a critical analysis of treatment and suggestions for prevention. Am. Rev. Resp. Dis. (1971) 103:887.
103. BROWN CV: Acute isoniazid poisoning. Am. Rev. Resp. Dis. (1972) 105:206-216.
104. FRIEDMAN SA: Death following massive ingestion of isoniazid. Am. Rev. Respir. Dis. (1969) 100:859-862.
105. PILIERO PJ, FISH DG: Isoniazid-induced β-hydroxybutyric acidosis. Ann. Int. Med. (2001) 134:799.
106. HANKINS DG, SAXENA K, FAVILLE RJ, WARREN bJ: Profound acidosis caused by isoniazid ingestion. Am. J. Emerg. Med. (1987) 5:165-166.
107. WASON S, LACOUTURE PG, LOVEJOY FH JR: Single high-dose pyridoxine treatment for isoniazid overdose. JAMA (1981) 246:1102-1104.
108. COYER JR, NICHOLSON DP: Isoniazid-induced convulsions: part II - experimental. South. Med. J. (1976) 69:296-297.
109. COYER JR, NICHOLSON DP: Isoniazid-induced convulsions: part I - clinical. South. Med. J. (1976) 69:294-296.
110. NOLAN CM, ELARTH AM, BARR HW: Intentional isoniazid overdose in young Southeast Asian refugee women. Chest (1988) 93:803-806.
111. BOICE JD, FRAUMENI JF JR: Late effects following isoniazid therapy. Am. J. Public Health (1980) 70:987-989.
112. HOWE GR, LINDSAY J, COPPOCK E, MILLER AB: Isoniazid exposure in relation to cancer incidence and mortality in a cohort of tuberculosis patients. Int. J. Epi. (1979) 8:305-312.
113. DESTA Z, SOUKHOVA NV, FLOCKHART DA: Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of cYP2C19 and cYP3A. Antimicrobial Agents Chemother. (2001) 45:382-392.
114. MURPHY R, SWARTZ R, WATKINS PB: Severe acetaminophen toxicity in a patient receiving isoniazid. Ann. Int. Med. (1990) 113:799-800.
115. HIRAOKA K, NAGATA N, KAWAJIRI T et al.: Paradoxical pleural response to antituberculous chemotherapy and isoniazid-induced lupus. Respiration (1998) 65:152-155.
116. SMITH PR, D'CRUZ D, RAFTERY MJ, DODD SM, HELBERT M, SKINNER CJ: Drug-induced lupus nephritis in HIV infection. Rheumatology (1999) 38:1017-1031.
117. ROTHFIELD NF, BIERER WF, GARFIELD JW: Isoniazid induction of antinuclear antibodies - a prospective study. Ann. Int. Med. (1978) 88:650-652.
118. ALARCON-SEGOVIA D, FISHBEIN E, ALCALA H: Isoniazid acetylation rate and development of anti-nuclear antibodies upon isoniazid treatment. Arthritis Rheum. (1971) 14:748-752.
119. SMITH CK, DURACK DT: Isoniazid and reaction to cheese. Ann. Int. Med. (1978) 88:520-521.
120. LEJONC JL, GUSMINI D, BROCHARD P: Isoniazid and reaction to cheese. Ann. Int. Med. (1979) 91:793.
121. KAHANA LM, TODD E: Histamine poisoning in a patient on isoniazid. Canada Diseases Weekly Report (1981) 7:79-80.
122. TOUTOUNGI M, CARROLL RLA, ENRICO JF, PEREY L: Cheese, wine, and isoniazid. Lancet (1985) 326:671.
123. SENANAYAKE N, VYRAVANATHAN S, KANAGASURIYAM S: Cerebrovascular accident after a 'Skipjack' reaction in a patient taking isoniazid. Br. Med. J. (1978) 2:1127-1128.
124. URAGODA CG: Histamine poisoning in tuberculous patients after ingestion of tuna fish. Am. Rev. Respir. Dis. (1980) 121:157-159.
125. ASAI S, SHIMODA T, HARA K, FUJIWARA K: Occupational asthma caused by isonicotinic acid hydrazide (INH) inhalation. J. Allergy Clin. Immunol. (1987) 80:578-582.
126. POLOSA R, COLOMBRITA R, PROSPERINI C, CACCIOLA R: A case of acute deterioration in asthma symptoms induced by isoniazid prophylaxis. Respir. Med. (1997) 91:438-440.
127. BURTON MJ, BURTON KJ, CHUKA-OKOSA CM, BAILEY RL: Plummeting lenses in the tB Clinic. Lancet (2002) 360:138.
128. STEPHENSON I, WISELKA MJ, QUALIE MJ: Acute pancreatitis induced by isoniazid in the treatment of tuberculosis. Am. J. Gastroenterol. (2001) 96:2271-2272.
129. OVALI F, SAMANCI N, SEVINC E, DAGOGLU T: Isoniazid and hypoglycaemia in a premature infant. J. Paediatr. Child Health (2004) 40:490-492.
130. ACOCELLA G, CONTI R: Interaction of rifampicin with other drugs. Tubercle (1980) 61:171-177.
131. POLESKY A, FARBER HW, GOTTLIEB DJ et al.: Rifampin preventive therapy for tuberculosis in boston's homeless. Am. J. Respir. Crit. Care Med. (1996) 154:1473-1477.
132. VILLARINO ME, R IDZON R, WEISMULLER PC: Rifampin preventive therapy for tuberculosis infection - experience with 157 adolescents. Am. J. Respir. Crit. Care Med. (1997) 155:1735-1738.
133. HONG KONG CHEST SERVICE/TUBERCULOSIS RESEARCH CENTRE, MADRAS/BRITISH MEDICAL RESEARCH COUNCIL: A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am. Rev. Respir. Dis. (1992) 145:36-41.
134. YEE D, VALIQUETTE C, PELLETIER M, PARISIEN I, ROCHER I, MENZIES D: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. (2003) 167:1472-1477.
135. COOK SV, FUJIWARA PI, FRIEDEN TR: Rates and risk factors for discontinuation of rifampicin. Int. J. Tuberc. Lung Dis. (2000) 4:118-122.
136. AQUINAS M, ALLAN WGL, HORSFALL PAL et al.: Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br. Med. J. (1972) 1:765-771.
137. GIRLING DJ, HITZE KL: Adverse reactions to rifampicin in antituberculosis regimens. J. Antimicrob. Chemother. (1977) 3:115-132.
138. TSANKOV N, ANGELOVA I: Rifampin in dermatology. Clinics Dermatol. (2003) 21:50-55.
139. DOGRA S, KANWAR AJ: Pifampicin-induced burning: an unusual presentation. Acta Derm. Venereol. (2003) 83:56.
140. PATEL GK, ANSTEY AV: Rifampicin-induced lupus erythematosus. Clin. Exp. Dermatol. (2001) 26:260-262.
141. BOLAN G, LAURIE RE, BROOME CV: Red man syndrome: Inadvertent administration of an excessive dose of rifampin to children in a day-care center. Pediatrics (1986) 77:633-635.
142. SINGAPORE TUBERCULOSIS SERVICE/BRITISH MEDICAL RESEARCH COUNCIL: Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore - the results up to 30 months. Am. Rev. Respir. Dis. (1977) 116:807-820.
143. POOLE G, STRADLING P, WORLLEDGE S: Potentially serious side-effects of high-dose twice-weekly rifampicin. Postgrad. Med. J. (1971) 47:742-747.
144. MEHTA YS, JIJINA FF, BADAKERE SS, PATHARE AV, MOHANTY D: Rifampin-induced immune thrombocytopenia. Tubercle Lung Dis. (1996) 77:558-562.
145. POOLE G, STRADLING P, WORLLEDGE S: Potentially serious side effects of high-dose twice-weekly rifampicin. Br. Med. J. (1971) 3:343-347.
146. PEREIRA J, HIDALGO P, OCQUETEAU M et al.: Glycoprotein ib/IX complex is the target in rifampicin-induced immune thrombocytopenia. Br. J. Hematol. (2000) 110:907-910.
147. AHRENS N, GENTH R, SALAMA A: Belated diagnosis in three patients with immune haemolytic anemia. Br. J. Haematol. (2002) 117:441-443.
148. KOBAYASHI K, HARUTA T, MAEDA H, KUBOTA M, NISHIO T: Cerebral hemorrhage associated with vitamin K deficiency in congenital tuberculosis treated with isoniazid and rifampin. Pediatr. Infect. Dis. J. (2002) 21:1088-1090.
149. LANGE P, OUN H, FULLER S, TURNEY JH: Eosinophilic colitis due to rifampicin. Lancet (1994) 344:1296-1297.
150. NAKAJIMA A, YAJIMA S, SHIRAKURA T et al.: Rifampin-associated pseudomembranous colitis. J. Gastroenterol. (2000) 35:299-303.
151. SMITH SJ, LEE AJ, MADDIX DS, CHOW AW: Pill-induced esophagitis caused by oral rifampicin. Ann. Pharmacother. (1999) 33:27-31.
152. DE VRIESE AS, ROBBRECHT DL, VANHOLDER RC, VOGELAERS DP, LAMEIRE NH: Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am. J. Kidney Dis. (1998) 31:108-115.
153. KISTLER A, LAPPIN DWP, COWARD RA: Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis Type 1 in a patient on antituberculous therapy with rifampicin. Nephrol. Dial. Transplant. (1999) 14:243-244.
154. YOSHIOKA K, SATAKE N, KASAMATU Y, NAKAMURA Y, SHIKATA N: Rapidly progressive glomerulonephritis due to rifampicin therapy. Nephron (2002) 90:116-118.
155. OGATA H, KUBO M, TAMAKI K, HIRAKATA H, OKUDA S, FUJISHIMA M: Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis. Nephron (1998) 78:319-322.
156. MEHANDRU S, GOEL A: A reversible cause of acute renal failure. Postgrad. Med. J. (2001) 77:478-480.
157. KOHNO K, MIZUTA Y, YOSHIDA T et al.: Minimal change nephrotic syndrome associated with rifampicin treatment. Nephrol. Dial. Transplant. (2000) 15:1056-1059.
158. COVIC A, GOLDSMITH DJA, SEGALL L et al.: Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol. Dial. Transplant. (1998) 13:924-929.
159. RIBERA E, AZUAJE C, LOPEZ RM et al.: Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). J. Acquir. Immune Defic. Syndr. (2005) 40:317-323.
160. FUJIWARA PI, CLEVENBERCH P, DLODLO RA: Management of adults living with HIV/AIDS in low-income, high-burden settings, with special reference to persons with tuberculosis. Int. J. Tuberc. Lung Dis. (2005) 9:946-958.
161. STEPHENSON I, QUALIE M, WISELKA MJ: Hepatic failure and encephalopathy attributed to an interaction between acetaminophen and rifampicin. Am. J. Gastroenterol. (2001) 96:1310-1311.
162. PRATT TH: Rifampin-induced organic brain syndrome. JAMA (1979) 241:2421-2422.
163. KUNICHIKA N, MIYAHARA N, KOTANI K, TAKEYAMA H, HARADA M, TANIMOTO M: Pneumonitis induced by rifampicin. Thorax (2002) 57:1000-1001.
164. ASHITANI J, YANAGI S, ARIMURA Y, SANO A, MUKAE H: Acute respiratory distress syndrome induced by rifampicin with high levels of neutrophil and eosinophil products in bronchoalveolar lavage fluid. Respiration (2003) 70:541-543.
165. CAYLEY FE, MAJUMDAR SK: Ocular toxicity due to rifampicin. Br. Med. J. (1976) 1:199-200.
166. LEES AW, ALLAN GW, SMITH J, TYRRELL WF, FALLON RJ: Rifampin plus isoniazid in initial therapy of pulmonary tuberculosis and rifampin and ethambutol in retreatment cases. Chest (1972) 61:579-582.
167. TAKASU N, YAMADA T, MIURA H et al.: Rifampicin-induced early phase hyperglycemia in humans. Am. Rev. Respir. Dis. (1982) 125:23-27.
168. TAKASU N, TAKARA M, KOMIYA I: Rifampin-induced hypothyroidism in patients with hashimoto's thyroiditis. N. Engl. J. Med. (2005) 352:518-519.
169. JENNER PJ, ELLARD GA, ALLAN WGL, SINGH D, GIRLING DJ, NUNN AJ: Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore. Tubercle (1981) 62:175-179.
170. DANAN G, PESSAYRE D, LARREY D, BENHAMOU JP: Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again. Lancet (1981) 318:1056-1057.
171. CORBELLA XC, VADILLO M, CABELLOS C, FERNANDEZ-VILADRICH P, RUFI G: Hypersensitivity hepatitis due to pyrazinamide. Scand. J. Infect. Dis. (1995) 27:93-94.
172. KNOBEL B, BUYANOWSKY G, DAN M, ZAIDEL L: Pyrazinamide-induced granulomatous hepatitis. J. Clin. Gastroenterol. (1997) 24:264-266.
173. DURAND F, BERNUAU J, PESSAYRE D et al.: Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology (1995) 21:929-932.
174. HAAPANEN J, GILL R, RUSSELL WF JR, KASS I: Re-treatment of pulmonary tuberculosis - experiences with various combinations of pyrazinamide, cycloserine and kanamycin in patients excreting tubercle bacilli resistant to both streptomycin and isoniazid. Am. Rev. Respir. Dis. (1960) 82:843-852.
175. SHORR AF, TROTTA R: PZA hypersensitivity. Chest (1996) 109:855-856.
176. MAURYA V, PANJABI C, SHAH A: Pyrazinamide-induced photoallergy. Int. J. Tuberc. Lung. Dis. (2001) 5:1075-1076.
177. RIBI C, HAUSER C: Adverse reactions to pyrazinamide. Allergy (2002) 57:964-965.
178. GIRLING DJ: Adverse effects of antituberculosis drugs. New Ethicals (1982) 123-147.
179. HONG KONG TUBERCULOSIS TREATMENT SERVICES/BRITISH MEDICAL RESEARCH COUNCIL: Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong. Tubercle (1976) 57:81-95.
180. TOSUN AK, KOCA NT, KARATAS GK: Acute gouty arthritis during pyrazinamide treatment: a case report. Mod. Rheumatol. (2004) 14:306-308.
181. SANCHEZ-ALBISUA I, VIDAL L, JOYA-VERDE C, DEL CASTILLO F, DE JOSE MI, GARCIA-HORTELANO J: Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children. Pediatr. Infect. Dis. J. (1997) 16:760-763.
182. TREECE GL, MAGNUSSEN CR, PATTERSON JR, TSCHUDY DP: Exacerbation of porphyria during treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. (1976) 113:233-237.
183. LEIBOLD JE: The ocular toxicity of ethambutol and its relation to dose. Ann. N. Y. Acad Sci. (1966) 135:904-909.
184. GRIFFITH DE, BROWN-ELLIOTT BA, SHEPHERD S, MCLARTY J, GRIFFITH L, WALLACE RJ JR: Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. (2005) 172:250-253.
185. MELAMUD A, KOSMORSKY GS, LEE MS: Ocular ethambutol toxicity. Mayo Clin. Proc. (2003) 78:1409-1411.
186. SCHILD HS, FOX BC: Rapid-onset reversible ocular toxicity from ethambutol therapy. Am. J. Med. (1991) 90:404-406.
187. SJOERDSMA T, KAMERMANS M, SPEKREIJSE H: Effect of the tuberculostaticum ethambutol and stimulus intensity on chromatic discrimination in man. Vision Research (1999) 39:2955-2962.
188. TREBUCQ A: Should ethambutol be recommended for routine treatment of tuberculosis in children? a review of the literature. Int. J. Tuberc. Lung Dis. (1997) 1:12-15.
189. KUROKAWA I, NAKAHIGASHI Y, TERAMACHI M: Erythema multiforme-type drug eruption due to ethambutol with eosiniphilia and liver dysfunction. Int. J. Antimicrob. Agents (2003) 21:596-597.
190. LAI TYY, CHAN WM, LAM DSC, LIM E: Multifical electroretinogram demonstrated macular toxicity associated with ethambutol related optic neuropathy. Br. J. Ophthalmol. (2005) 89:774-775.
191. GULLIFORD M, MACKAY AD, PROWSE K: Cholestatic jaundice caused by ethambutol. Br. Med. J. (1986) 292:866.
192. WONG PC, YEW WW, WONG CF, CHOI HY: Ethambutol-induced pulmonary infiltrates with eosinophilia and skin involvement. Eur. Respir. J. (1995) 8:866-868.
193. KHANNA BK: Acute gouty arthritis following ethambutol therapy. Br. J. Dis. Chest (1980) 74:409-410.
194. KAUBE H, MUMMEL P, KOEPPEN S: Ethambutol related headache in HIV infection: sensitisation to normal cSF pressure? A case report. J. Neurol. Neurosurg. Psychiatry (2000) 68:535-536.
195. KWON SH, KIM JH, YANG JO, LEE EY, HONG SY: Ethambutol-induced acute renal failure. Nephrol. Dial. Transplant. (2004) 19:1335-1336.
196. DE JAGER P, VAN ALTENA R: Hearing loss and nephrotoxocity in long-term aminoglycoside treatment in patients with tuberculosis. Int. J. Tuberc. Lung Dis. (2002) 6:622-627.
197. ROMANO A, VIOLA M, DI FONSO M, ROSARIA PERRONE M GAETA F, ANDRIOLO M: Anaphylaxis to streptomycin. Allergy (2002) 57:1087-1088.
198. PARRERON TM, NDIR MC, AUBRON C, HOVETTE P: Drug rash with eosinophilia and systemic symptoms (DRESS) due to streptomycin. Acta Derm. Venereol. (2003) 84:92-93.
199. LAL S, SINGHAL SN, BURLEY DM, CROSSLEY C: Effect of rifampicin and isoniazid on liver function. Br. Med. J. (1972) 1:148-150.
200. SCHABERG T: The dark side of antituberculosis therapy: adverse events involving liver function. Eur. Respir. Rev. (1995) 4:1247-1249.
201. KANDULA NR, DWORKIN MS, CARROLL MR, LAUDERDALE DS: Tuberculosis prevention in mexican immigrants - limitations of short-course therapy. Am. J. Prev. Med. (2004) 26:163-166.
202. LOBATO MN, REVES RR, JASMER RM, GRABAU JC, BOCK NN, CHANG N: Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest (2005) 127:1296-1303.
203. STEELE MA, BURK RF, DESPREZ RM: Toxic hepatitis with isoniazid and rifampin - a meta-analysis. Chest (1991) 99:465-471.
204. TELEMAN MD, CHEE CBE, EARNEST A, WANG YT: Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int. J. Tuberc. Lung Dis. (2002) 6:699-705.
205. GONZALEZ MONTANER LJ, DAMBROSI A, MANASSERO M, DAMBROSI V, DAMBROSI ML: Adverse effects of antituberculosis drugs causing changes in treatment. Tubercle (1982) 63:291-294.
206. VAN DEN BRANDE P, VAN STEENBERGEN W, VERVOORT C, DEMEDTS M: Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. (1995) 152:1705-1708.
207. CORRIGAN D, PATON J: Hepatic enzyme abnormalities in children on triple therapy for tuberculosis. Pediatr. Pulmonol. (1999) 27:37-42.
208. PARTHASARATHY R, RAGHUPATI SARMA G, JANARDHANAM B: Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle (1986) 67:99-108.
209. COMBS DL, O'BRIEN RJ, GEITER LJ: USPHS Tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann. Int. Med. (1990) 112:397-406.
210. O'BRIEN RJ, LONG MW, CROSS BA, LYLE MA, SNIDER DE JR: Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics (1983) 72:491-499.
211. ORMEROD LP: Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch. Dis. Child (1998) 78:169-171.
212. BOCK NN, ROGERS T, TAPIA JR, HERRON GD, DEVOE B, GEITER LJ: Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest (2001) 119:833-837.
213. CHIASSON RE, ARMSTRONG J, STAFFORD J, GOLUB J, BUR S: Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA (2002) 288:165-166.
214. HORN DL, HEWLETT D JR, ALFALLA C, PETERSON S, OPAL SM: Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N. Engl. J. Med. (1994) 330:1241.
215. MWINGA A, HOSP M, GODFREY-FAUSSETT P: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS (1998) 12:2447-2457.
216. HALSEY NA, COBERLY JS, DESORMEAUX J et al.: Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet (1998) 351:786-792.
217. WHALEN CC, JOHNSON JL, OKWERA A et al.: A trial of three regimens to prevent tuberculosis in ugandan adults with the human immunodeficiency virus. N. Engl. J. Med. (1997) 337:801-808.
218. LEE AM, MENNONE JZ, JONES RC, PAUL WS: Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int. J. Tuberc. Lung Dis. (2002) 6:995-1000.
219. RIDZON R, MEADOR J, MAXWELL R, HIGGINS K, WEISMULLER P, ONORATO IM: Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin. Infect. Dis. (1997) 24:1264-1265.
220. PAPASTAVROS T, DOLOVICH LR, HOLBROOK A, WHITEHEAD L, LOEB M: Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. Canad. Med. Ass. J. (2002) 167:131-136.
221. LOU HX, SHULLO MA, MCKAVENEY TP: Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacother. (2002) 22:701-704.
222. GOLDBERG SV, DUCHIN JS, SHIELDS T, NOLAN CM: Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. (1999) 160:508-512.
223. JASMER RM, SNYDER DC, CHIN DP et al.: Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis - an outcome and cost-effectiveness analysis. Am. J. Respir. Crit. Care Med. (2000) 162:1648-1652.
224. MCNAB BD, MARCINIUK DD, ALVI RA, TAN L, HOEPPNER VH: Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in canadian plains aborigines. Am. J. Respir. Crit. Care Med. (2000) 162:989-993.
225. STOUT JE, ENGEMANN JJ, CHENG AC, FORTENBERRY ER, HAMILTON CD: Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am. J. Respir. Crit. Care Med. (2003) 167:824-827.
226. DUTT AK, MOERS D, STEAD WM: Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin - community physicians' seven-year experience with mainly outpatients. Am. J. Med. (1984) 77:233-242.
227. JASMER RM, SAUKKONEN JJ, BLUMBERG HM et al.: Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann. Int. Med. (2002) 137:640-647.
228. MCNEILL L, ALLEN M, ESTRADA C, COOK P: Pyrazinamide and rifampin versus isoniazid for the treatment of latent tuberculosis - improved completion rates but more hepatotoxicity. Chest (2003) 123:102-106.
229. LEUNG CC, LAW WS, CHANG KC et al.: Initial experience on rifampin and pyrazinamide versus isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest (2003) 124:2112-2118.
230. VAN HEST R, BAARS H, KIK S et al.: Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin. Infect. Dis. (2004) 39:488-496.
231. GORDIN F, CHAISSON RE, MATTS JP et al.: Rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons - an international randomized trial. JAMA (2000) 283:1445-1450.
232. OHKAWA K, HASHIGUCHI M, OHNO K et al.: Risk factors for antituberculous chemotherapy-induced hepatotoxicity in japanese pediatric patients. Clin. Pharmacol. Ther. (2002) 72:220-226.
233. HONG KONG CHEST SERVICE/BRITISH MEDICAL RESEARCH COUNCIL: Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet (1981) 317:171-174.
234. KELTEN MK, VAN DER MERWE CA: Random variation in tuberculin sensitivity in schoolchildren - serial skin testing before and after preventive treatment for tuberculosis. Am. Rev. Respir. Dis. (1989) 140:1001-1006.
235. DUTT AK, MOERS D, STEAD WW: Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy. Am. Rev. Respir. Dis. (1989) 139:867-870.
236. DUTT AK, MOERS D, STEAD WW: Smear-negative, culture-positive pulmonary tuberculosis: six-month chemotherapy with isoniazid and rifampin. Am. Rev. Respir. Dis. (1990) 141:1232-1235.
237. SNIDER DE JR, LONG MW, CROSS FS, FARER LS: Six-months isoniazid-rifampin therapy for pulmonary tuberculosis - report of a united states public health service cooperative trial. Am. Rev. Respir. Dis. (1984) 129:573-579.
238. HONG KONG CHEST SERVICE/TUBERCULOSIS RESEARCH CENTRE, MADRAS, BRITISH MEDICAL RESEARCH COUNCIL: A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear negative tuberculosis - results at 5 years. Am. Rev. Respir. Dis. (1989) 139:871-876.
239. HONG KONG CHEST SERVICE/TUBERCULOSIS RESEARCH CENTRE, MADRAS, BRITISH MEDICAL RESEARCH COUNCIL: A controlled trial comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am. Rev. Respir. Dis. (1991) 143:262-267.
240. HONG KONG CHEST SERVICE/BRITISH MEDICAL RESEARCH COUNCIL: Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide - results at 30 months. Am. Rev. Respir. Dis. (1991) 143:700-706.
241. SINGAPORE TUBERCULOSIS SERVICE/BRITISH MEDICAL RESEARCH COUNCIL: Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am. Rev. Respir. Dis. (1991) 143:707-712.
242. SECOND EAST AFRICAN/BRITISH MEDICAL RESEARCH COUNCIL STUDY: Controlled clinical trial of four short-course (6-months) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet (1974) 304:1100-1106.
243. VADASZ I: Adverse reactions to isoniazid. Bult Int. Union Tuberc. (1974) 49:294-300.
244. ZIERSKI M, BEK E: Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study. Tubercle (1980) 61:41-49.
245. CROSS FS, LONG MW, BANNER AS, SNIDER DE JR: Rifampin-induced therapy of alcoholic and nonalcoholic tuberculous patients in a US Public health service cooperative therapy trial. Am. Rev. Respir. Dis. (1980) 122:349-353.
246. UNGO JR, JONES D, ASHKIN D et al.: Antituberculosis drug-induced hepatotoxicity - the role of hepatitis C virus and the human immunodeficiency virus. Am. J. Respir. Crit. Care Med. (1998) 157:1871-1876.
247. LEE BH, KOH WJ, CHOI MS et al.: Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest (2005) 127:1304-1311.
248. WONG WM, WU PC, YUEN MF et al.: Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatol. (2000) 31:201-206.
249. TAHAOGLU K, ATAC C, SEVIM T et al.: The management of anti-tuberculosis drug-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. (2001) 5:65-69.
250. QUANTRILL SJ, WOODHEAD MA, BELL CE, HARDY CC, HUTCHISON AJ, GOKAL R: Side-effects of antituberculosis drug treatment in patients with chronic renal failure. Eur. Respir. J. (2002) 20:440-443.
251. SNIDER DE JR, POWELL KE: Should women taking antituberculosis drugs breast-feed? Arch. Int. Med. (1984) 144:589-590.
252. CZEIZEL AE, ROCKENBAUER M, OLSEN J, SORENSEN HT: A population-based case-control study of oral anti-tuberculosis drug treatment during pregnancy. Int. J. Tuberc. Lung Dis. (2001) 5:564-568.